Psoriatic Arthritis Treatment - Global Stategic Business Report

The global market for Psoriatic Arthritis Treatment was estimated at US$10.8 Billion in 2024 and is projected to reach US$16.3 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Psoriatic Arthritis Treatment market.

Global 'Psoriatic Arthritis Treatment' Market - Is the Era of Personalized Autoimmune Care Here?

Is Rising Disease Awareness Catalyzing Early Diagnosis and Treatment?

Psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, is gaining recognition due to rising public and clinical awareness. Previously underdiagnosed or misdiagnosed, PsA is now being identified earlier, leading to timely therapeutic intervention and better outcomes. Increased awareness campaigns by healthcare organizations, dermatology clinics, and rheumatology societies are encouraging patients to report early joint discomfort or stiffness. Innovations in imaging and biomarker testing are enhancing diagnostic accuracy, while patient support communities are driving proactive care-seeking behavior. These factors are boosting early-stage treatment initiation, a crucial determinant of disease progression and quality of life.

Are Biologic and Targeted Therapies Transforming the Treatment Landscape?

The PsA treatment market has undergone a dramatic shift with the advent of biologics and small molecule inhibitors. TNF inhibitors, IL-17 and IL-23 inhibitors, and JAK inhibitors have emerged as frontline therapies, offering more targeted immunomodulation with improved efficacy and reduced systemic side effects. As biologics become more affordable and biosimilars enter the market, access is expanding across different geographies. Additionally, oral therapies such as PDE4 inhibitors are providing more convenient options for patients unwilling or unable to use injectable biologics. Clinical guidelines are increasingly supporting early biologic use to prevent joint damage, further pushing demand for advanced therapies.

Is Patient-Centered Care Driving Treatment Customization?

Psoriatic arthritis manifests differently among patients, making personalized treatment strategies critical. Shared decision-making is gaining traction in rheumatology practices, with patients and providers working together to select therapies based on comorbidities, lifestyle preferences, and treatment goals. Digital health tools are helping track symptoms, adherence, and response to medication, enabling real-time adjustments to care plans. Patients are also more educated about potential side effects, access programs, and alternative treatment options. This shift toward individualized therapy and improved access support services is enhancing treatment satisfaction and persistence, reinforcing demand for diverse therapeutic offerings.

The Growth in the Psoriatic Arthritis Treatment Market Is Driven by Several Factors…

The growth in the psoriatic arthritis treatment market is driven by several factors including therapeutic innovation, broader diagnosis, and changing patient engagement dynamics. Technologically, the development of new biologic pathways and oral agents is expanding treatment options with higher efficacy and specificity. End-use growth is observed in rheumatology clinics and specialty pharmacies that provide coordinated care and insurance navigation. Consumer trends are shifting toward informed, proactive disease management with greater use of digital health tools and participation in clinical trials. Further, increasing pharmaceutical investments in autoimmune drug pipelines, rising prevalence in developed markets, and stronger reimbursement frameworks are reinforcing the expansion of PsA treatment offerings worldwide.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Biologics segment, which is expected to reach US$9.5 Billion by 2030 with a CAGR of a 6.3%. The Non-biologics segment is also set to grow at 8.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.9 Billion in 2024, and China, forecasted to grow at an impressive 11.0% CAGR to reach $3.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Psoriatic Arthritis Treatment Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Psoriatic Arthritis Treatment Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Psoriatic Arthritis Treatment Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Alvotech, Amgen Inc., AstraZeneca plc, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Psoriatic Arthritis Treatment market report include:

• AbbVie Inc.
• Alvotech
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion, Inc.
• Currax Pharmaceuticals LLC
• Eli Lilly and Company
• Janssen Pharmaceuticals (Johnson & Johnson)
• Merck & Co., Inc.
• MoonLake Immunotherapeutics
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.